Shopping Cart
Remove All
Your shopping cart is currently empty
SR-4835
Copy Product Info
🥰Excellent
Catalog No. T8325Cas No. 2387704-62-1
SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (TNBC) cells
SR-4835
Copy Product Info🥰Excellent
Purity: 99.79%
Catalog No. T8325Cas No. 2387704-62-1
SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (TNBC) cells
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $51 | In Stock | In Stock | |
| 5 mg | $122 | In Stock | In Stock | |
| 10 mg | $198 | In Stock | In Stock | |
| 25 mg | $297 | In Stock | In Stock | |
| 50 mg | $393 | In Stock | In Stock | |
| 100 mg | $587 | In Stock | In Stock | |
| 200 mg | $815 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.79%
Contact us for more batch information
Product Introduction
SR-4835 AI Summary
SR-4835 exhibits a range of bioactivities including inhibition of various kinases such as casein kinase 1delta, casein kinase 1epsilon, CDK12, and CDK13, as well as serine 2 phosphorylation of RNA polymerase II's Rbb1. It demonstrates growth inhibition in human U87 and MDA-MB-231 cells with very low GI50 values, and has shown antiproliferative activities against several cancer cell lines, exhibiting synergistic effects when combined with different compounds. The compound binds to CDK12 and CDK13 with varying affinities, presenting an IC50 value of 468.6 nM for the human CDK12/cyclinK complex and different dissociation constants for CDK12, CDK13, and GSK-3-beta proteins. It also exhibits inhibition of various cytochrome P450 enzymes. The compound’s effects on cell viability vary across different cell lines; it inhibits growth in HEK293T and U2OS cells, while showing both inhibitory and stimulatory effects in human fibroblast cells. Thermal Shift Assay results indicate that SR-4835 influences the thermal stability of multiple protein domains, suggesting diverse interactions with different protein regions..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (TNBC) cells |
| Targets&IC50 | CDK12:98 nM (Kd), CDK12:99 nM, CDK13:4.9 nM (Kd) |
| Molecular Weight | 499.36 |
| Formula | C21H20Cl2N10O |
| Cas No. | 2387704-62-1 |
| Smiles | Cn1cc(cn1)-n1cnc2c(NCc3nc4cc(Cl)c(Cl)cc4[nH]3)nc(nc12)N1CCOCC1 |
| Relative Density. | 1.72 g/cm3 (Predicted) |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||
| Solubility Information | DMSO: 4.8 mg/mL (9.61 mM), Sonication is recommended.  | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy SR-4835 | purchase SR-4835 | SR-4835 cost | order SR-4835 | SR-4835 chemical structure | SR-4835 formula | SR-4835 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.